Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Prepublished online as a Blood First Edition Paper on July 12, 2002; DOI 10.1182/blood-2002-03-0996.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2002-03-0996v1
100/9/3063    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Richardson, P. G.
Right arrow Articles by Anderson, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Richardson, P. G.
Right arrow Articles by Anderson, K. C.
Related Collections
Right arrow Neoplasia
Right arrow Plenary Papers
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1 November 2002, Vol. 100, No. 9, pp. 3063-3067

PLENARY PAPER

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Paul G. Richardson, Robert L. Schlossman, Edie Weller, Teru Hideshima, Constantine Mitsiades, Faith Davies, Richard LeBlanc, Laurence P. Catley, Deborah Doss, Kathleen Kelly, Mary McKenney, Julie Mechlowicz, Andrea Freeman, Reggie Deocampo, Rebecca Rich, Joan J. Ryoo, Dharminder Chauhan, Kathe Balinski, Jerome Zeldis, and Kenneth C. Anderson

From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ.

Thalidomide (Thal) can overcome drug resistance in multiple myeloma (MM) but is associated with somnolence, constipation, and neuropathy. In previous in vitro studies, we have shown that the potent immunomodulatory derivative of thalidomide (IMiD) CC-5013 induces apoptosis or growth arrest even in resistant MM cell lines and patient cells, decreases binding of MM cells to bone marrow stromal cells (BMSCs), inhibits the production in the BM milieu of cytokines (interleukin-6 [IL-6], vascular endothelial growth factor [VEGF], tumor necrosis factor-alpha [TNF-alpha ]) mediating growth and survival of MM cells, blocks angiogenesis, and stimulates host anti-MM natural killer (NK) cell immunity. Moreover, CC-5013 also inhibits tumor growth, decreases angiogenesis, and prolongs host survival in a human plasmacytoma mouse model. In the present study, we carried out a phase 1 CC-5013 dose-escalation (5 mg/d, 10 mg/d, 25 mg/d, and 50 mg/d) study in 27 patients (median age 57 years; range, 40-71 years) with relapsed and refractory relapsed MM. They received a median of 3 prior regimens (range, 2-6 regimens), including autologous stem cell transplantation and Thal in 15 and 16 patients, respectively. In 24 evaluable patients, no dose-limiting toxicity (DLT) was observed in patients treated at any dose level within the first 28 days; however, grade 3 myelosuppression developed after day 28 in all 13 patients treated with 50 mg/d CC-5013. In 12 patients, dose reduction to 25 mg/d was well tolerated and therefore considered the maximal tolerated dose (MTD). Importantly, no significant somnolence, constipation, or neuropathy has been seen in any cohort. Best responses of at least 25% reduction in paraprotein occurred in 17 (71%) of 24 patients (90% confidence interval [CI], 52%-85%), including 11 (46%) patients who had received prior Thal. Stable disease (less than 25% reduction in paraprotein) was observed in an additional 2 (8%) patients. Therefore, 17 (71%) of 24 patients (90% CI, 52%-85%) demonstrated benefit from treatment. Our study therefore provides the basis for the evaluation of CC-5013, either alone or in combination, to treat patients with MM at earlier stages of disease.

© 2002 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
M. Wang, M. A. Dimopoulos, C. Chen, M. T. Cibeira, M. Attal, A. Spencer, S. V. Rajkumar, Z. Yu, M. Olesnyckyj, J. B. Zeldis, et al.
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Blood, December 1, 2008; 112(12): 4445 - 4451.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. S. Lin
Lenalidomide: what is the right dose in CLL?
Blood, June 1, 2008; 111(11): 5268 - 5268.
[Full Text] [PDF]


Home page
JCOHome page
L. A. Andritsos, A. J. Johnson, G. Lozanski, W. Blum, C. Kefauver, F. Awan, L. L. Smith, R. Lapalombella, S. E. May, C. A. Raymond, et al.
Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol., May 20, 2008; 26(15): 2519 - 2525.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. V. Rajkumar, L. Rosinol, M. Hussein, J. Catalano, W. Jedrzejczak, L. Lucy, M. Olesnyckyj, Z. Yu, R. Knight, J. B. Zeldis, et al.
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma
J. Clin. Oncol., May 1, 2008; 26(13): 2171 - 2177.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. A. Chanan-Khan and B. D. Cheson
Lenalidomide for the Treatment of B-Cell Malignancies
J. Clin. Oncol., March 20, 2008; 26(9): 1544 - 1552.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. A. Kyle and S. V. Rajkumar
Multiple myeloma
Blood, March 15, 2008; 111(6): 2962 - 2972.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Brenner, A. Gondos, and D. Pulte
Recent major improvement in long-term survival of younger patients with multiple myeloma
Blood, March 1, 2008; 111(5): 2521 - 2526.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Jagannath
Is tandem autotransplantation necessary in myeloma?
Blood, February 15, 2008; 111(4): 1751 - 1752.
[Full Text] [PDF]


Home page
JCOHome page
W. Bensinger
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
W. Matsui, Q. Wang, J. P. Barber, S. Brennan, B. D. Smith, I. Borrello, I. McNiece, L. Lin, R. F. Ambinder, C. Peacock, et al.
Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
Cancer Res., January 1, 2008; 68(1): 190 - 197.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Raza, J. A. Reeves, E. J. Feldman, G. W. Dewald, J. M. Bennett, H. J. Deeg, L. Dreisbach, C. A. Schiffer, R. M. Stone, P. L. Greenberg, et al.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Blood, January 1, 2008; 111(1): 86 - 93.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
N. Chen, H. Lau, L. Kong, G. Kumar, J. B. Zeldis, R. Knight, and O. L. Laskin
Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis
J. Clin. Pharmacol., December 1, 2007; 47(12): 1466 - 1475.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
M. Dimopoulos, A. Spencer, M. Attal, H. M. Prince, J.-L. Harousseau, A. Dmoszynska, J. S. Miguel, A. Hellmann, T. Facon, R. Foa, et al.
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
N. Engl. J. Med., November 22, 2007; 357(21): 2123 - 2132.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
D. M. Weber, C. Chen, R. Niesvizky, M. Wang, A. Belch, E. A. Stadtmauer, D. Siegel, I. Borrello, S. V. Rajkumar, A. A. Chanan-Khan, et al.
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
N. Engl. J. Med., November 22, 2007; 357(21): 2133 - 2142.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
M. A. Dimopoulos, V. L. Souliotis, A. Anagnostopoulos, C. Bamia, A. Pouli, I. Baltadakis, E. Terpos, S. A. Kyrtopoulos, and P. P. Sfikakis
Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma
Haematologica, November 1, 2007; 92(11): 1505 - 1512.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
K. V. Rao
Lenalidomide in the treatment of multiple myeloma
Am. J. Health Syst. Pharm., September 1, 2007; 64(17): 1799 - 1807.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
B Sirohi, R Powles, D Lawrence, J Treleaven, S Kulkarni, A Leary, C Rudin, C Horton, and G Morgan
An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-{alpha}2b in patients with multiple myeloma maintained on a steady dose of interferon-{alpha}2b
Ann. Onc., August 1, 2007; 18(8): 1388 - 1394.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Dispenzieri, C. J. Klein, and M. L. Mauermann
Lenalidomide therapy in a patient with POEMS syndrome
Blood, August 1, 2007; 110(3): 1075 - 1076.
[Full Text] [PDF]


Home page
BloodHome page
T. Kiziltepe, T. Hideshima, K. Ishitsuka, E. M. Ocio, N. Raje, L. Catley, C.-Q. Li, L. J. Trudel, H. Yasui, S. Vallet, et al.
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells
Blood, July 15, 2007; 110(2): 709 - 718.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, F. Samaniego, J. Romaguera, and Q. Yi
Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways
Blood, June 15, 2007; 109(12): 5455 - 5462.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Kiziltepe, T. Hideshima, L. Catley, N. Raje, H. Yasui, N. Shiraishi, Y. Okawa, H. Ikeda, S. Vallet, S. Pozzi, et al.
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Mol. Cancer Ther., June 1, 2007; 6(6): 1718 - 1727.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Kobune, H. Chiba, J. Kato, K. Kato, K. Nakamura, Y. Kawano, K. Takada, R. Takimoto, T. Takayama, H. Hamada, et al.
Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism
Mol. Cancer Ther., June 1, 2007; 6(6): 1774 - 1784.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson
New Drugs for Myeloma
Oncologist, June 1, 2007; 12(6): 664 - 689.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Y. Kristinsson, O. Landgren, P. W. Dickman, A. R. Derolf, and M. Bjorkholm
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
J. Clin. Oncol., May 20, 2007; 25(15): 1993 - 1999.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. Fonseca and A. K. Stewart
Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach
Mol. Cancer Ther., March 1, 2007; 6(3): 802 - 810.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Muto, M. Hori, Y. Sasaki, A. Saitoh, I. Yasuda, T. Maekawa, T. Uchida, K. Asakura, T. Nakazato, T. Kaneda, et al.
Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor
Mol. Cancer Ther., March 1, 2007; 6(3): 987 - 994.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Verhelle, L. G. Corral, K. Wong, J. H. Mueller, L. Moutouh-de Parseval, K. Jensen-Pergakes, P. H. Schafer, R. Chen, E. Glezer, G. D. Ferguson, et al.
Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells
Cancer Res., January 15, 2007; 67(2): 746 - 755.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. Sanchorawala, D. G. Wright, M. Rosenzweig, K. T. Finn, S. Fennessey, J. B. Zeldis, M. Skinner, and D. C. Seldin
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
Blood, January 15, 2007; 109(2): 492 - 496.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Dispenzieri, M. Q. Lacy, S. R. Zeldenrust, S. R. Hayman, S. K. Kumar, S. M. Geyer, J. A. Lust, J. B. Allred, T. E. Witzig, S. V. Rajkumar, et al.
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
Blood, January 15, 2007; 109(2): 465 - 470.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
P. Richardson, C. Mitsiades, R. Schlossman, I. Ghobrial, T. Hideshima, D. Chauhan, N. Munshi, and K. Anderson
The Treatment of Relapsed and Refractory Multiple Myeloma
Hematology, January 1, 2007; 2007(1): 317 - 323.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Chanan-Khan, K. C. Miller, L. Musial, D. Lawrence, S. Padmanabhan, K. Takeshita, C. W. Porter, D. W. Goodrich, Z. P. Bernstein, P. Wallace, et al.
Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study
J. Clin. Oncol., December 1, 2006; 24(34): 5343 - 5349.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
R Baz, E Walker, M. Karam, T. Choueiri, R. Jawde, K Bruening, J Reed, B Faiman, Y Ellis, C Brand, et al.
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy
Ann. Onc., December 1, 2006; 17(12): 1766 - 1771.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. G. Richardson, E. Blood, C. S. Mitsiades, S. Jagannath, S. R. Zeldenrust, M. Alsina, R. L. Schlossman, S. V. Rajkumar, K. R. Desikan, T. Hideshima, et al.
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Blood, November 15, 2006; 108(10): 3458 - 3464.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
S. Singhal and J. Mehta
Multiple Myeloma
Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1322 - 1330.
[Abstract] [Full Text] [PDF]


Home page
Arch DermatolHome page
H. P. Sviggum, M. D. P. Davis, S. V. Rajkumar, and A. Dispenzieri
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Arch Dermatol, October 1, 2006; 142(10): 1298 - 1302.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Tefferi, J. Cortes, S. Verstovsek, R. A. Mesa, D. Thomas, T. L. Lasho, W. J. Hogan, M. R. Litzow, J. B. Allred, D. Jones, et al.
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Blood, August 15, 2006; 108(4): 1158 - 1164.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Anderson, M. Gries, N. Kurihara, T. Honjo, J. Anderson, V. Donnenberg, A. Donnenberg, I. Ghobrial, M. Y. Mapara, D. Stirling, et al.
Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
Blood, April 15, 2006; 107(8): 3098 - 3105.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
B. Barlogie, G. Tricot, E. Anaissie, J. Shaughnessy, E. Rasmussen, F. van Rhee, A. Fassas, M. Zangari, K. Hollmig, M. Pineda-Roman, et al.
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
N. Engl. J. Med., March 9, 2006; 354(10): 1021 - 1030.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial Transplant